Milestone pharmaceuticals inc. (MIST)
CashFlow / Yearly
Dec'19Dec'18
Operating activities
Net loss for the period

-55,229

-23,185

Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of property and equipment

38

10

Share-based compensation expense (note 4)

1,191

633

Changes in operating assets and liabilities:
Other receivables

-119

271

Research and development tax credits receivable

288

-137

Prepaid expenses

447

1,298

Accounts payable and accrued liabilities

3,520

2,876

Income taxes payable (receivable)

-56

52

Net cash used in operating activities

-51,152

-21,046

Investing activities
Acquisition of property and equipment

413

5

Acquisition of short-term investments

35,000

3,029

Redemption of short-term investments

35,029

19,032

Net cash (used in) provided by investing activities

-384

15,998

Financing activities
Net proceeds from initial public offering

85,363

-

Issuance of common shares on exercise of share options (note 4)

44

461

Net cash provided by financing activities

85,407

80,115

Net increase in cash and cash equivalents during the period

33,871

75,067

Class D1 preferred shares
Issuance of preferred shares

-

64,719

Class D2 preferred shares
Issuance of preferred shares

-

14,935